Drug Profile
MVT 5873
Alternative Names: 5B1-(sLeA)-therapeutic; Anti-CA19.9 antibody; anti-sialyl Lewisa antibody; BNT-321; HuMab MVT-5873; HuMab-5B1; HuMab-5B1 antibody; MVT-5873Latest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator MabVax Therapeutics
- Developer MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Sarah Cannon Research Institute
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cholangiocarcinoma; Colorectal cancer; Pancreatic cancer
- No development reported Cancer; Non-small cell lung cancer; Small cell lung cancer
Most Recent Events
- 18 Jan 2024 Interim adverse events, efficacy, pharmacokinetics and pharmacodynamics data from a phase-I trial in Pancreatic cancer presented at the Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 24 Nov 2023 Phase-I/II clinical trials in Pancreatic cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (IV) (BioNTech pipeline, November 2023)